Free Trial

Sartorius Aktiengesellschaft Q4 2022 Earnings Report

Sartorius Aktiengesellschaft logo
$192.75 0.00 (0.00%)
(As of 12/20/2024 ET)

Sartorius Aktiengesellschaft EPS Results

Actual EPS
$2.30
Consensus EPS
$1.65
Beat/Miss
Beat by +$0.65
One Year Ago EPS
N/A

Sartorius Aktiengesellschaft Revenue Results

Actual Revenue
$1.08 billion
Expected Revenue
$873.35 million
Beat/Miss
Beat by +$210.85 million
YoY Revenue Growth
N/A

Sartorius Aktiengesellschaft Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

Sartorius Aktiengesellschaft Earnings Headlines

Sartorius 9-month Underlying Net Profit Declines; Confirms 2024 Guidance
Sartorius vz earnings: here's what Wall Street expects
2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis
Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.
See More Sartorius Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sartorius Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sartorius Aktiengesellschaft and other key companies, straight to your email.

About Sartorius Aktiengesellschaft

Sartorius Aktiengesellschaft (OTCMKTS:SARTF) provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.

View Sartorius Aktiengesellschaft Profile

More Earnings Resources from MarketBeat

Upcoming Earnings